Sequentify

Executive Summary

Sequentify is an Israeli biotech company revolutionizing next-generation sequencing (NGS) library preparation with its flagship InfiniSeq platform. The platform reduces the traditional multi-hour workflow to a streamlined four-step process taking just 3.15 hours, significantly cutting turnaround time and costs. Designed to be platform-agnostic, InfiniSeq supports high-throughput pooling and is compatible with leading NGS sequencers, making it suitable for clinical diagnostics, research, and agricultural genomics. Founded in 2020 and headquartered in Rehovot, Israel, the company has raised $7 million in funding and employs 50–200 people. Its technology addresses a critical bottleneck in NGS workflows, enabling faster, more cost-effective sample processing for applications ranging from oncology and genetic disorder screening to crop genomics. Sequentify’s differentiation lies in its simplicity, speed, and versatility. Unlike competing library preparation kits that require multiple steps and lengthy protocols, InfiniSeq's all-in-one approach minimizes hands-on time and reduces error rates. The company targets the rapidly growing NGS diagnostics market, where demand for rapid, scalable solutions is rising. With initial commercial traction in research settings, Sequentify is now positioning InfiniSeq for clinical adoption. Upcoming milestones include achieving CE-IVD certification, securing strategic partnerships with diagnostic laboratories, and closing a Series A funding round to scale manufacturing and sales. If successful, Sequentify could become a standard tool in clinical NGS workflows, driving adoption in precision medicine and agricultural breeding programs.

Upcoming Catalysts (preview)

• Q4 2026CE-IVD certification for InfiniSeq clinical diagnostic use70% success
• H1 2027Strategic partnership with a major diagnostic laboratory60% success
• Q3 2026Series A funding round to scale commercialization80% success